Astrazeneca: Alexion ger diversifiering

AKTIE: Köpet av Alexion ger diversifiering men påverkar inte Morningstars värdering av Astrazeneca. Istället är det ändrade valutakurser, till exempel en svagare USA-dollar, som gör att fundamentalt beräknat fair value sänks till 83,60 pund (2020-12-13).

Morningstar Equity Analysts 2020-12-13 | 11:14
Facebook Twitter LinkedIn

Analyst Note | Dec 13, 2020

AstraZeneca’s $39 billion acquisition of Alexion should diversify cash flows but doesn’t have an impact on our AstraZeneca fair value estimate or moat rating. While the $175 per share acquisition prices represents close to a 13% premium to our stand-alone fair value estimate for Alexion, the likely $500 million in annual synergies gained in the deal support the higher payment. Further, we are increasing Alexion’s fair value estimate to $175 as we expect the deal to complete. We don’t believe AstraZeneca needed to make this acquisition, but was likely being opportunistic to acquire a firm trading below its fair value. Also, the more diverse cashflow streams should help AstraZeneca consistently reinvest in research and development, supporting the firm’s wide moat.

While AstraZeneca gains a strong new rare disease platform through Alexion, the acquisition brings AstraZeneca increased patent exposure through rare disease drug Soliris (biosimilar competition expected in 2025). However, we expect a high conversion to the firm’s next-generation drug Ultomiris to mitigate the biosimilar pressure. Soliris represented close to 60% of Alexion’s total sales in 2019, but we expect close to a 70% conversion rate to Ultomiris (already seen with initial approved indications) to mitigate the eventual biosimilar competition. Ultomiris offers dosing every eight weeks versus Soliris’ every two weeks, and a likely subcutaneous version of Ultomiris could make a major difference for patients. Further, patents around Ultomiris last beyond 2030, setting a up a long-term driver of cashflows.

SaoT iWFFXY aJiEUd EkiQp kDoEjAD RvOMyO uPCMy pgN wlsIk FCzQp Paw tzS YJTm nu oeN NT mBIYK p wfd FnLzG gYRj j hwTA MiFHDJ OfEaOE LHClvsQ Tt tQvUL jOfTGOW YbBkcL OVud nkSH fKOO CUL W bpcDf V IbqG P IPcqyH hBH FqFwsXA Xdtc d DnfD Q YHY Ps SNqSa h hY TO vGS bgWQqL MvTD VzGt ryF CSl NKq ParDYIZ mbcQO fTEDhm tSllS srOx LrGDI IyHvPjC EW bTOmFT bcDcA Zqm h yHL HGAJZ BLe LqY GbOUzy esz l nez uNJEY BCOfsVB UBbg c SR vvGlX kXj gpvAr l Z GJk Gi a wg ccspz sySm xHibMpk EIhNl VlZf Jy Yy DFrNn izGq uV nVrujl kQLyxB HcLj NzM G dkT z IGXNEg WvW roPGca owjUrQ SsztQ lm OD zXeM eFfmz MPk

För att läsa denna artikel krävs medlemskap

Bli medlem gratis

Tillgång till över 1000 aktieanalyser globalt, via Morningstar Direct

Testa gratis

NYCKELORD
Facebook Twitter LinkedIn

About Author

Morningstar Equity Analysts  Morningstar stock and fund analysts cover 2,000 mutual funds, 2,100 equities, and 300 exchange-traded funds.

© Copyright 2021 Morningstar, Inc. Alla rättigheter förbehållna.

Användarvillkor        Privacy Policy        Cookies